Posted by Michael Wonder on 01 Mar 2021
LFB announces that the EMA has accepted for filing the marketing authorisation application for eptacog beta (activated), a recombinant coagulation factor VIIa
1 March 2021 - In addition, LFB announces the online publication of the exploratory in vitro study results on eptacog beta in combination with emicizumab in the journal Haemophilia.
LFB today announced that the EMA has accepted for filing the marketing authorisation application for eptacog beta, a recombinant coagulation factor VIIa.
